Pharming Group ( (PHAR) ) has shared an announcement.
On April 3, 2025, Pharming Group N.V. announced the filing of its 2024 Annual Report and Form 20-F with the U.S. Securities and Exchange Commission. This filing marks a significant step in maintaining transparency and compliance with regulatory standards, potentially impacting the company’s operations and stakeholder confidence.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is engaged in the commercialization and development of a portfolio of innovative medicines, including small molecules and biologics. Headquartered in Leiden, the Netherlands, Pharming operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific.
YTD Price Performance: -20.41%
Average Trading Volume: 6,573
Technical Sentiment Signal: Buy
Current Market Cap: $554.2M
See more insights into PHAR stock on TipRanks’ Stock Analysis page.